√ Beyond the Abstract - A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
√ BERKELEY, CA (UroToday.com) - Degarelix is a new gonadotropin-releasing hormone (GnRH) receptor blocker that binds to pituitary GnRH receptors, immediately blocking gonadotropin release, which results in rapid suppression of testosterone production1.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
